Therapeutic regimen for hypertension
Inventors
Snyder, Eric • Sprissler, Ryan • Snyder, Scott C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11674179-B2
Publication Date
2023-06-13
Expiration Date
Abstract
The invention relates to improved methods, devices, and kits for identifying and implementing an appropriate treatment regimen for subjects suffering from hypertension.
Core Innovation
The patent describes a method for treating an individual patient having hypertension by determining the individual patient’s genotype for each of fourteen single nucleotide polymorphisms. The genotype is obtained from a tissue or fluid sample, followed by polymerase amplification of segments using primers relating to the fourteen single nucleotide polymorphisms to produce nucleotide fragments of the patient’s genotype, and the nucleotide fragments are introduced into a time-of-flight mass spectrometer to identify nucleotide sequences of the patient’s genotype at defined SNP loci.
After genotype identification, the method administers a first line therapy antihypertensive drug selected from diuretic, vasodilator, and beta blocker drug categories. The diuretic drugs include a thiazide diuretic drug, a loop diuretic drug, or an amiloride potassium sparing diuretic drug, and the vasodilator drugs include an angiotensin II receptor antagonist drug or an ACE inhibitor drug.
Drug administration is selected based on specific homozygous genotype conditions at the fourteen SNPs, including decision rules that map homozygous cytosine, thymine, adenine, guanine, or deletion at particular variable positions to particular drug categories. The disclosed approach further implements genotype determination using polymerase amplification and time-of-flight mass spectrometry.
Claims Coverage
The document includes one independent claim that covers genotype-guided selection of a first line antihypertensive drug based on determinations at fourteen specified single nucleotide polymorphism loci. The independent claim is supported by dependent claims that refine how the fourteen SNPs are determined and how polymerase amplification is performed, and that add comparative genotype constraints between procedure groupings.
Genotype-guided selection of first-line antihypertensive therapy
Administering a first line therapy antihypertensive drug selected from a diuretic drug, a vasodilator drug, and a beta blocker drug, wherein the selection is determined according to specific homozygous genotype rules at fourteen specified single nucleotide polymorphisms.
Genotype determination using polymerase amplification and time-of-flight mass spectrometry
Obtaining patient DNA from a tissue or fluid sample, conducting polymerase amplification of segments using primers relating to the fourteen single nucleotide polymorphisms to produce nucleotide fragments of the patient’s genotype, and introducing the nucleotide fragments into a time-of-flight mass spectrometer to identify nucleotide sequences of the patient’s genotype.
SNP determination sequentially or simultaneously
Determining the fourteen single nucleotide polymorphisms either sequentially or simultaneously as part of the genotype-determining steps.
PCR followed by SNE extension to produce SNP-specific fragments
Performing polymerase amplification including a first PCR amplification step and a second SNE extension step using SNE primers and all four nucleotide terminators to produce fourteen SNE extended sequences whose 3′ termini are the variable nucleotides of the respective SNPs.
Comparative homozygosity constraint across genotype-to-drug procedure groups
Where the patient’s genotype for procedures c, d, e, and f does not have homozygous single nucleotide sequences of procedures a and b.
Overall, the claim coverage centers on determining fourteen specified SNP genotypes from patient DNA using polymerase amplification and time-of-flight mass spectrometry, then administering a first-line antihypertensive drug using homozygosity-based selection rules, with refinements covering sequential versus simultaneous SNP determination, PCR plus SNE extension fragment generation, and cross-group genotype constraints.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?